FEDERICO, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 68.112
EU - Europa 34.217
AS - Asia 27.369
SA - Sud America 3.993
Continente sconosciuto - Info sul continente non disponibili 1.720
AF - Africa 760
OC - Oceania 204
Totale 136.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 66.849
GB - Regno Unito 11.148
IT - Italia 7.314
SG - Singapore 7.228
CN - Cina 6.983
RU - Federazione Russa 3.657
HK - Hong Kong 3.304
BR - Brasile 2.993
VN - Vietnam 2.976
DE - Germania 2.601
SE - Svezia 2.567
FI - Finlandia 1.730
BD - Bangladesh 1.636
TR - Turchia 1.472
UA - Ucraina 1.446
FR - Francia 1.263
KR - Corea 769
CA - Canada 640
IN - India 588
BG - Bulgaria 546
JP - Giappone 453
NL - Olanda 385
ID - Indonesia 373
AR - Argentina 329
IE - Irlanda 265
MX - Messico 247
IQ - Iraq 208
ZA - Sudafrica 204
ES - Italia 192
AU - Australia 184
AE - Emirati Arabi Uniti 169
PK - Pakistan 165
EC - Ecuador 145
PL - Polonia 140
BE - Belgio 138
MY - Malesia 135
CL - Cile 133
CO - Colombia 133
AT - Austria 132
MA - Marocco 129
BZ - Belize 109
CZ - Repubblica Ceca 105
EG - Egitto 103
SA - Arabia Saudita 99
CH - Svizzera 90
RO - Romania 86
VE - Venezuela 85
PH - Filippine 81
UZ - Uzbekistan 80
IR - Iran 75
IL - Israele 67
TN - Tunisia 66
LT - Lituania 65
TH - Thailandia 65
NP - Nepal 63
TW - Taiwan 59
DZ - Algeria 56
KE - Kenya 56
CR - Costa Rica 51
PY - Paraguay 49
PE - Perù 46
JO - Giordania 44
PT - Portogallo 43
AZ - Azerbaigian 41
JM - Giamaica 39
UY - Uruguay 39
DK - Danimarca 35
BO - Bolivia 32
DO - Repubblica Dominicana 30
HU - Ungheria 30
NO - Norvegia 30
EU - Europa 29
KZ - Kazakistan 28
ET - Etiopia 26
GR - Grecia 26
OM - Oman 26
KG - Kirghizistan 24
EE - Estonia 22
HN - Honduras 22
GT - Guatemala 21
PA - Panama 20
LB - Libano 19
RS - Serbia 19
BH - Bahrain 17
NZ - Nuova Zelanda 17
PR - Porto Rico 17
AL - Albania 16
LY - Libia 16
SK - Slovacchia (Repubblica Slovacca) 16
SV - El Salvador 16
TT - Trinidad e Tobago 16
AM - Armenia 15
LV - Lettonia 15
MD - Moldavia 15
SI - Slovenia 15
HR - Croazia 14
AO - Angola 13
BY - Bielorussia 13
GE - Georgia 13
NI - Nicaragua 13
Totale 134.427
Salva come PNG Salva come JPEG
Città #
Southend 8.520
Ashburn 6.731
Fairfield 6.447
Santa Clara 4.965
Singapore 4.504
Woodbridge 3.560
Hong Kong 3.182
Houston 2.970
Chandler 2.930
Moscow 2.713
Jacksonville 2.639
Seattle 2.428
Wilmington 2.276
Dearborn 2.118
Cambridge 2.087
Hefei 2.032
San Jose 2.010
Ann Arbor 1.639
Beijing 1.414
Nyköping 1.349
Council Bluffs 1.319
London 1.307
Los Angeles 1.222
Helsinki 1.206
Chicago 926
Ho Chi Minh City 888
The Dalles 826
New York 816
Izmir 783
Milan 701
Hanoi 656
Frankfurt am Main 648
San Diego 628
Princeton 595
Seoul 586
Sofia 528
Buffalo 512
Eugene 477
Modena 473
Dallas 467
Rome 407
Lauterbourg 396
Shanghai 346
Salt Lake City 336
Redwood City 308
Columbus 297
Des Moines 279
São Paulo 266
Jakarta 263
Phoenix 249
Tokyo 222
Dublin 221
Munich 215
Dong Ket 206
Atlanta 204
Bremen 169
Orem 162
Boardman 157
Bologna 156
Elk Grove Village 150
Falls Church 143
San Francisco 143
Toronto 139
Tampa 131
Da Nang 129
Brooklyn 118
Turin 118
Haiphong 116
Manchester 115
Naples 115
Miami 113
Montreal 113
Denver 112
Verona 110
Norwalk 109
Belize City 106
Philadelphia 105
Rio de Janeiro 103
Warsaw 94
Guangzhou 92
North Bergen 91
Las Vegas 90
Chennai 88
Nuremberg 85
Brussels 83
Padova 83
Mexico City 80
Amsterdam 79
Florence 78
Johannesburg 78
Brno 77
Sterling 76
Palermo 75
Kunming 74
Stockholm 72
Baghdad 70
Miano 69
Nanjing 69
Turku 69
Lancaster 68
Totale 90.965
Salva come PNG Salva come JPEG
Nome #
Clinical activity and safety of combination immunotherapy with interferon-(2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. 2.928
SPLENECTOMY AFTER INITIAL THERAPY WITH ALPHA-IFN IN PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) - A MULTICENTER STUDY BY THE ITALIAN COOPERATIVE GROUP FOR HCL - PRELIMINARY-RESULTS 2.654
Hb Hasharon: studio di un nucleo familiare 1.494
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12 1.157
Eritropoiesi extramidollare intratoracica. Considerazioni clinico radiologiche su due casi di talassemia minor 1.139
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial 943
Cancer profile in Eastern Libya: incidence and mortality in the year 2004. 792
Sindrome mediastinica da mieloblastoma quale manifestazione d'esordio di leucemia mieloide acuta 786
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial 770
Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin 766
Cancer incidence in eastern Libya: The first report from the Benghazi Cancer Registry, 2003 755
Estimates of cancer burden in Italy 710
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 705
Risk assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. 701
Pattern of cancer risk in person with AIDS in Italy inthe HAART era 698
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 635
IMPACT Working Group: effectiveness of service screening: a case-control study to assess breast cancer mortalità reduction. 612
The italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk 576
Caratterizzazione morfo-funzionale delle cellule reticolari dendritiche. 564
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 530
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 526
T-cell lymphoma in South America and Europe. 514
Il linfoma mantellare 511
EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century 497
Il morbo di Hodgkin sclero-nodulare. Studio clinico-patologico 487
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 485
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project 483
Nonpegylated liposomal doxorubicin (Myocet) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO 18 trial 476
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 469
Transformed follicular lymphoma 464
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 462
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 443
Splenic marginal zone lymphoma: a prognostic model for clinical use. 437
Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study 419
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 417
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 415
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma 410
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma - The experience of the gruppo italiano studio linfomi 408
Follicular lymphoma international prognostic index. 404
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 404
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 403
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 393
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. 393
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations 392
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 391
Revised response criteria for malignant lymphoma. 384
Treatment of indolent B-cell nonfollicular lymphomas: Final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi 380
Protein expression patterns associated with advanced stage ovarian cancer 377
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 377
High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy 377
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 373
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 371
PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract 367
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience 366
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 366
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 364
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 360
Patologia non neoplastica del follicolo linfatico 359
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 358
Prognosis of follicular lymphomas 356
Italian family with two independent mutations:3358T/A in BRCA1 and 8756delA in BRCA2 genes. 352
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 348
Patogenesi complessa di una emopatia sistemica: la tricoleucemia 348
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 344
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: Results of a prospective, multicenter study of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 343
Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies 343
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study 342
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 340
Anthracyclines: A cornerstone in the management of non-Hodgkin's lymphoma 340
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study 339
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines 337
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study 337
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma 337
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 335
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 335
Concordance between four European centre of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. 333
Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 331
ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi 330
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 330
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 329
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. 329
PET-CT for staging and early response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study 327
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 322
CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease - A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL) 321
Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy 319
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence 319
Bone marrow uptake of liposome-entrapped spin label after liver blockade with empty liposomes 318
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 318
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 317
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 317
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 317
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 316
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi 315
Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-cell Lymphoma Project 315
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 315
PROMECE-CYTABOM VS MACOP-B IN ADVANCED AGGRESSIVE NON-HODGKINS-LYMPHOMA - LONG-TERM RESULTS OF A MULTICENTER STUDY OF THE ITALIAN LYMPHOMA STUDY-GROUP (GISL) 313
Effects of thymostimulin with combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma. 312
A RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY COMPARING A LEVOSULPIRIDE-BASED AND A METOCLOPRAMIDE-BASED COMBINATION IN THE PREVENTION OF PROMECE-CYTABOM-INDUCED EMESIS 311
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 311
Totale 49.724
Salva come PNG Salva come JPEG
Categoria #
all - tutte 479.766
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 479.766
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229.896 0 1.341 1.251 792 318 521 593 608 1.062 702 1.647 1.061
2022/20239.552 1.028 902 642 808 1.197 1.459 252 1.007 1.215 176 504 362
2023/20247.778 329 432 421 538 1.586 462 810 1.161 160 284 698 897
2024/202520.415 1.371 985 282 1.358 3.603 2.583 1.651 1.112 2.432 716 1.892 2.430
2025/202640.137 2.134 1.579 3.222 3.757 5.055 2.794 4.330 1.997 3.475 3.255 4.296 4.243
2026/20271.797 1.717 80 0 0 0 0 0 0 0 0 0 0
Totale 136.375